查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1715626

按药物类别、给药途径、分销和最终用户分類的肺动脉高血压市场—2025-2030 年全球预测

Pulmonary Arterial Hypertension Market by Drug Class, Route Of Administration, Distribution, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计肺动脉高血压市场规模到 2024 年将达到 91.2 亿美元，到 2025 年将达到 97.7 亿美元，复合年增长率为 7.46%，到 ​​2030 年将达到 140.4 亿美元。

主要市场统计数据
基准年2024年 91.2亿美元
预计2025年 97.7亿美元
预测年份 2030 140.4亿美元
复合年增长率（%） 7.46%

肺动脉高血压(PAH) 是一种严重且复杂的心血管疾病，其特征是肺动脉血压升高，如果治疗不当，会导致右心室劳损并最终导致心臟衰竭。这种疾病不仅带来了重大的临床挑战，而且对全球医疗保健系统产生了重大影响。本报告对 PAH 市场进行了全面的介绍，并提供了对当前趋势、转型转变、细分复杂性、区域差异以及推动治疗策略创新的主要企业的专家分析。

诊断方法的最新进展，加上对 PAH 所涉及的分子路径的深入了解，正在推动治疗模式的快速发展。因此，人们越来越重视治疗方法减轻症状负担同时延长预期寿命的治疗方法。相关人员现在必须平衡功效、安全性和市场准入，同时也要应对不断变化的监管和经济状况。

本摘要中概述的叙述不仅阐明了当前的市场状况，而且还预测了由科学突破和行业专家之间的策略合作所推动的未来发展。该报告深入探讨了由于更广泛的经济变化、技术进步和临床实践的转变而导致的市场格局的演变，使其成为决策者和政策制定者的重要工具。该分析利用前沿研究和多学科见解，强调了基于证据的策略和数据主导的决策在应对多环芳烃带来的挑战中的关键作用。

改变肺动脉高血压市场

近年来，肺动脉高血压治疗领域发生了重大变化。治疗发展的创新和新技术的出现重新定义了治疗通讯协定和市场预期。生物医学研究的重要突破不仅提高了诊断的准确性，而且促进了改善患者预后和生活品质的标靶治疗的创造。从传统化疗到生物技术解决方案的演变凸显了精准医疗的更广泛趋势。

製药公司和研究机构正在共同努力，利用分子生物学和基因分析在 PAH 治疗中的潜力，提高现有治疗的特异性和整体成功率。随着这些新治疗方法越来越普及，监管机构也同时适应新的模式，以确保安全标准跟上技术创新的快速步伐。

此外，数位健康平台、远端医疗和先进监测设备的整合正在重新配置患者参与度和治疗后追踪通讯协定。这些技术进步使得即时监测患者生物标记成为可能，提供了十年前无法想像的个人化医疗保健解决方案。由此形成的由研究、技术和临床应用组成的相互联繫的生态系统将预示着以患者为中心的护理和市场活力的新时代的到来。正是这些因素的汇合不断改变着竞争格局，挑战着传统观念，并在对抗多环芳烃的斗争中释放了前所未有的机会。

深入了解市场区隔

对 PAH 市场的详细研究揭示了一个多方面的细分框架，为治疗和分销策略提供了清晰的指导。根据药物类别，我们对治疗方法进行了深入分析，包括构成目前治疗方法，例如内皮素受体拮抗剂、磷酸二酯酶 5 抑制剂和类前列腺素。透过这种细分，可以全面评估每种药物类别的临床疗效、安全性以及在更广泛的治疗领域中的定位。

同样重要的分析涉及给药途径。这里我们研究了静脉注射、口服和皮下给药方式的市场。给药途径的多样性不仅影响患者的依从性和便利性，而且在决定整体治疗结果方面也起着关键作用。此外，我们还将考虑按通路制定分销策略，例如医院药局、网路药局和零售药局。这种分层提供了对可访问性、供应链效率以及传统和现代分销网络之间不断变化的动态的洞察。

最后，基于最终用户人口统计的细分可以深入了解推动市场趋势的需求区隔。分析的重点涵盖学术和研究机构、诊所和医院等主要群体。这项全面的细分策略将使相关人员能够识别市场机会、调整策略倡议并优化资源配置，以适应不断变化的患者需求和不断发展的医疗实践。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 肺动脉高血压盛行率及早期诊断的增加
      • 政府对肺动脉高血压的支持和监管核准
    • 限制因素
      • 治疗费用昂贵且保险覆盖范围有限
    • 机会
      • 肺动脉高血压药物研发投资与资金激增
      • 建立伙伴关係，共同开发和商业化肺动脉高血压的药物
    • 任务
      • 药物研发中的高监管障碍和合规问题
  • 市场区隔分析
    • 药物类别：对降低肺血管阻力的内皮素受体拮抗剂的需求不断增长
    • 给药途径：静脉注射越来越受到人们的青睐，因为它可以即时、可控制地输送强效药物。
    • 分销：对线上药局提高便利性和可近性的需求不断增长
    • 最终用户：医院在复杂的 PAH 管理中的重要性日益增加
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章肺动脉高血压市场（依药物类别）

  • 内皮素受体拮抗剂
  • 磷酸二酯酶5抑制剂
  • 类前列腺素

第七章肺动脉高血压市场（依给药途径）

  • 静脉
  • 口服
  • 皮下

第八章肺动脉高血压市场分布

  • 医院药房
  • 网路药局
  • 零售药局

第九章肺动脉高血压市场（依最终用户）

  • 学术研究所
  • 诊所
  • 医院

10.美洲肺动脉高血压市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

11. 亚太地区肺动脉高血压市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12. 欧洲、中东和非洲肺动脉高血压市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Alembic Pharmaceuticals Limited
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Cipla Limited
  • CMP Pharma, Inc.
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Gossamer Bio, Inc.
  • Gyre Therapeutics, Inc.
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Limited
  • United Therapeutics Corporation
Product Code: MRR-030D347B0AD6

The Pulmonary Arterial Hypertension Market was valued at USD 9.12 billion in 2024 and is projected to grow to USD 9.77 billion in 2025, with a CAGR of 7.46%, reaching USD 14.04 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 9.12 billion
Estimated Year [2025] USD 9.77 billion
Forecast Year [2030] USD 14.04 billion
CAGR (%) 7.46%

Pulmonary arterial hypertension (PAH) is a formidable and complex cardiovascular condition characterized by elevated blood pressure in the pulmonary arteries, leading to right ventricular strain and eventual heart failure if inadequately managed. The condition not only poses significant clinical challenges but also drives substantial implications for healthcare systems globally. This report introduces an extensive exploration of the PAH market, providing expert analysis of current trends, transformational shifts, segmentation intricacies, regional variances, and the key players driving innovation in treatment strategies.

Recent advancements in diagnostic methodologies, coupled with a growing understanding of the molecular pathways involved in PAH, have catalyzed a rapid evolution in treatment paradigms. As a result, there is an increased emphasis on both established and emerging therapeutic approaches aimed at prolonging life expectancy while reducing symptom burden. Stakeholders are now compelled to balance considerations of efficacy, safety, and market access as they navigate an often evolving regulatory and economic landscape.

The narrative outlined in this summary not only delineates the state of the current market but also projects future developments fueled by scientific breakthroughs and strategic collaborations among industry experts. The report delves into how market conditions are being reshaped by broader economic changes, advancements in technology, and shifts in clinical practices, making it an indispensable tool for decision-makers and policy strategists alike. By leveraging cutting-edge research and cross-disciplinary insights, the analysis underscores the pivotal role of evidence-based strategies and data-driven decision-making in confronting the challenges posed by PAH.

Transformative Shifts in the Pulmonary Arterial Hypertension Landscape

The landscape of pulmonary arterial hypertension treatment has undergone significant transformation over recent years. Innovations in therapeutic development and the advent of new technologies have redefined treatment protocols and market expectations. Critical breakthroughs in biomedical research have not only improved diagnostic accuracy but also fostered the creation of targeted treatment modalities, which offer improved patient outcomes and quality of life. The evolution from conventional chemical therapies to biotechnologically driven solutions underscores a broader trend toward precision medicine.

Pharmaceutical companies and research institutions have collaboratively forged pathways to harness the potential of molecular biology and genetic profiling in PAH management, thereby enhancing both the specificity and overall success rates of available treatments. As these emerging therapies gain traction, regulatory agencies are simultaneously adapting to new paradigms, ensuring that safety standards keep pace with the rapid pace of innovation.

Moreover, the integration of digital health platforms, telemedicine, and advanced monitoring devices has reconfigured patient engagement and post-treatment follow-up protocols. These technological advancements enable real-time monitoring of patient biomarkers and offer personalized healthcare solutions that were unimaginable a decade ago. The resultant interconnected ecosystem of research, technology, and clinical application heralds a new era of patient-centered care and market dynamism. It is this confluence of factors that continues to fuel transformative shifts in the competitive landscape, challenging established norms and unlocking unprecedented opportunities in the fight against PAH.

Deep Dive into Market Segmentation Insights

A granular examination of the PAH market reveals a multifaceted segmentation framework that provides clarity on treatment and distribution strategies. The market is rigorously analyzed by drug class, with detailed insights into therapies involving Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, and Prostanoids, which form the cornerstone of current therapeutic regimens. This segmentation ensures a thorough evaluation of each drug category's clinical efficacy, safety profile, and positioning within the broader treatment landscape.

An equally critical dimension of analysis pertains to the route of administration. Here, the market is scrutinized under the modalities of Intravenous, Oral, and Subcutaneous delivery systems. The diversity in administration routes not only influences patient compliance and convenience but also plays a significant role in determining overall therapeutic outcomes. Furthermore, the distribution strategy is examined across channels that include Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. This stratification gives insight into accessibility, supply chain efficiencies, and the evolving dynamics between traditional and modern distribution networks.

Finally, the segmentation based on end-user demographics provides a window into the demand segments driving market trends. Analytical focus extends to key groups such as Academic and Research Institutions, Clinics, and Hospitals. This comprehensive segmentation strategy enables stakeholders to identify market opportunities, tailor strategic initiatives, and optimize resource allocation in alignment with shifting patient needs and evolving healthcare practices.

Based on Drug Class, market is studied across Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, and Prostanoids.

Based on Route Of Administration, market is studied across Intravenous, Oral, and Subcutaneous.

Based on Distribution, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.

Based on End User, market is studied across Academic & Research Institutions, Clinics, and Hospitals.

Comprehensive Analysis of Global Regional Dynamics

An exhaustive regional analysis highlights how distinct economic, regulatory, and demographic factors shape the PAH market across various territories. The Americas continue to be a major hub for innovative treatment strategies, buoyed by robust healthcare infrastructure and significant investments in research and development. Clinicians and market participants in this region benefit from coordinated care models and a high degree of regulatory oversight, which collectively help in the swift adoption of advanced therapies.

In parallel, the combined region of Europe, Middle East & Africa is witnessing dynamic shifts catalyzed by progressive health policies and enhanced cross-border collaborations. The integration of research initiatives across academic institutions has paved the way for addressing regional disparities in treatment access and affordability. Furthermore, these regions are well known for their rigorous clinical testing environments that add a layer of robustness to market data.

Emerging as a focal point, the Asia-Pacific region brings its own set of unique challenges and opportunities, with rapid urbanization, evolving patient awareness, and a surge in investments directed at improving healthcare delivery systems. The increasing prevalence of PAH, concomitant with a growing middle class that demands higher quality healthcare, is gradually transforming market strategies. Together, these regions form a comprehensive mosaic of global trends, each contributing nuanced insights into the overall market dynamics and paving the way for future innovations in treatment and distribution strategies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Illuminating the Role of Key Market Players

The competitive landscape of the PAH market is defined by a mix of established titans and emerging innovators, each contributing uniquely to the sector's growth trajectory. Leading companies such as Alembic Pharmaceuticals Limited and AstraZeneca PLC are at the forefront of research-driven initiatives, spearheading clinical trials and pioneering novel therapeutic approaches. Their historical commitment to quality and innovation has been further reinforced by the vigorous participation of other global entities like Aurobindo Pharma Limited, Bayer AG, and Boehringer Ingelheim GmbH.

Visionary organizations including Cipla Limited, CMP Pharma, Inc., and Dr. Reddy's Laboratories Limited have significantly enhanced treatment accessibility through robust production networks and strategic market collaborations. In parallel, industry giants such as Eli Lilly and Company, Gilead Sciences, Inc., and GlaxoSmithKline PLC continue to redefine market benchmarks through groundbreaking research and transformative patient care protocols. The market's competitive fabric is further woven by the contributions of emerging players such as Gossamer Bio, Inc. and Gyre Therapeutics, Inc., who are relentlessly pursuing innovative treatments that promise to disrupt traditional paradigms.

The influence of well-established entities like Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., and Lupin Limited is evidenced by their extensive product portfolios and commitment to expanding global outreach. The formidable presence of multinational corporations including Merck KGaA, Novartis AG, and Pfizer, Inc., alongside strategic efforts by Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Limited, and United Therapeutics Corporation, ensures that expertise, reliability, and continuous improvement remain at the core of the market's evolution. This network of industry leaders not only fosters healthy competition but also promotes collaborative endeavors that drive the frontier of PAH treatment forward.

The report delves into recent significant developments in the Pulmonary Arterial Hypertension Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Limited, AstraZeneca PLC, Aurobindo Pharma Limited, Bayer AG, Boehringer Ingelheim GmbH, Cipla Limited, CMP Pharma, Inc., Dr. Reddy's Laboratories Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline PLC, Gossamer Bio, Inc., Gyre Therapeutics, Inc., Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., Lupin Limited, Merck KGaA, Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Limited, and United Therapeutics Corporation. Strategic Recommendations for Industry Pioneers

In light of the multifaceted challenges and rapidly evolving market dynamics, industry leaders are urged to adopt a series of strategic recommendations designed to foster growth and sustainability. First, strengthening research and development initiatives remains paramount. Investment in cutting-edge technologies and fostering collaborations with academic institutions can accelerate the discovery of novel treatment modalities. Additionally, a keen focus on patient-centric care models is essential, particularly through the integration of digital health technologies that enhance real-time monitoring of disease progression. Stakeholders must also re-evaluate distribution channels, leveraging both traditional and digital marketplaces to ensure improved accessibility and streamlined logistics. Finally, ongoing risk assessment and adherence to evolving regulatory standards will be critical in maintaining market competitiveness and ensuring long-term success.

Conclusion: Charting the Future in Pulmonary Arterial Hypertension

The comprehensive analysis of the pulmonary arterial hypertension market underscores its remarkable dynamism and the potential for groundbreaking innovations in the near future. Amid an evolving therapeutic landscape marked by transformative research, diverse segmentation strategies, and robust regional variations, the market is poised to benefit from synergistic advancements that blend clinical insights with technological innovation. The interplay between established players and emerging innovators continues to redefine traditional paradigms, offering unparalleled opportunities to improve patient outcomes and expand treatment accessibility.

In summary, the insights presented in this report highlight pivotal trends, strategic challenges, and the collaborative spirit necessary to navigate a competitive market environment. As healthcare providers and decision-makers work together to harness these opportunities, the shared goal remains clear: to enhance the quality of life for patients suffering from PAH while simultaneously driving forward a new era of evidence-based, technology-driven care. The path forward is replete with challenges, but the potential to transform patient care and market dynamics stands as a testament to the resilience and capacity for innovation within the industry.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence and early diagnosis of pulmonary arterial hypertension
      • 5.1.1.2. Supportive government initiatives and regulatory approvals for pulmonary arterial hypertension
    • 5.1.2. Restraints
      • 5.1.2.1. High treatment costs and limited insurance coverage
    • 5.1.3. Opportunities
      • 5.1.3.1. Surging investments and funding for the advancement of pulmonary arterial hypertension drugs
      • 5.1.3.2. Partnership and collaborations to develop and commercialize pulmonary arterial hypertension drugs
    • 5.1.4. Challenges
      • 5.1.4.1. High regulatory hurdles and compliance issues in drug development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Rising need for endothelin receptor antagonists for reducing pulmonary vascular resistance
    • 5.2.2. Route Of Administration: Rising preference for intravenous administration for immediate and controlled delivery of potent medications
    • 5.2.3. Distribution: Growing demand for online pharmacies for enhanced convenience and broader accessibility
    • 5.2.4. End User: Rising significance of hospitals for complex PAH management
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pulmonary Arterial Hypertension Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Endothelin Receptor Antagonists
  • 6.3. Phosphodiesterase-5 Inhibitors
  • 6.4. Prostanoids

7. Pulmonary Arterial Hypertension Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Oral
  • 7.4. Subcutaneous

8. Pulmonary Arterial Hypertension Market, by Distribution

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Pulmonary Arterial Hypertension Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutions
  • 9.3. Clinics
  • 9.4. Hospitals

10. Americas Pulmonary Arterial Hypertension Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pulmonary Arterial Hypertension Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pulmonary Arterial Hypertension Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Corsair Pharma partners with InstantGMP to transform quality management for advanced transdermal pulmonary arterial hypertension therapy
    • 13.3.2. UK MHRA approves MSD's sotatercept therapy for pulmonary arterial hypertension
    • 13.3.3. XOMA Royalty Corporation strengthens its biotech pipeline with the acquisition of Pulmokine Inc.
    • 13.3.4. 35Pharma secures USD 53 million in Series C financing to accelerate clinical trials for HS135 in pulmonary hypertension
    • 13.3.5. BioCurate funds innovative research at Monash University to accelerate advanced treatment for pulmonary arterial hypertension
    • 13.3.6. Inhibikase Therapeutics secures USD 110 million in a private placement to fund its Phase 2b trial for IkT-001Pro
    • 13.3.7. NIH funds Cleveland Clinic-led trial evaluating novel therapeutics to reduce right-heart failure risk and mortality in pulmonary arterial hypertension patients
    • 13.3.8. Liquidia Corporation and Pharmosa Biopharm expand global strategic collaboration to enhance treatment options for PAH
    • 13.3.9. EC approval of Yuvanci marks a paradigm shift in pulmonary arterial hypertension treatment by offering Europe's first single-tablet combination therapy
    • 13.3.10. Liquidia Corporation secures tentative FDA approval for YUTREPIA in PAH and PH-ILD to enhance long-term market access and patient outcomes
    • 13.3.11. US FDA orphan drug designation for ZMA001 accelerates antibody development in phase 1a trials
    • 13.3.12. Inhibikase Therapeutics secures FDA new molecular entity designation for IkT-001Pro in pulmonary arterial hypertension
    • 13.3.13. Chiesi and Gossamer Bio collaborate to develop inhaled seralutinib to address pulmonary arterial hypertension
    • 13.3.14. Merck's FDA-approved Winrevair demonstrates significant clinical promise for pulmonary arterial hypertension
    • 13.3.15. The U.S. FDA grants approval for Johnson & Johnson's OPSYNVI to transform pulmonary arterial hypertension treatment
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. Johnson & Johnson Services, Inc.
    • 13.4.2. Merck KGaA
    • 13.4.3. United Therapeutics Corporation
    • 13.4.4. Cipla Limited

Companies Mentioned

  • 1. Alembic Pharmaceuticals Limited
  • 2. AstraZeneca PLC
  • 3. Aurobindo Pharma Limited
  • 4. Bayer AG
  • 5. Boehringer Ingelheim GmbH
  • 6. Cipla Limited
  • 7. CMP Pharma, Inc.
  • 8. Dr. Reddy's Laboratories Limited
  • 9. Eli Lilly and Company
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline PLC
  • 12. Gossamer Bio, Inc.
  • 13. Gyre Therapeutics, Inc.
  • 14. Hikma Pharmaceuticals PLC
  • 15. Johnson & Johnson Services, Inc.
  • 16. Lupin Limited
  • 17. Merck KGaA
  • 18. Novartis AG
  • 19. Pfizer, Inc.
  • 20. Sun Pharmaceutical Industries Limited
  • 21. Teva Pharmaceutical Industries Ltd.
  • 22. Torrent Pharmaceuticals Limited
  • 23. United Therapeutics Corporation

LIST OF FIGURES

  • FIGURE 1. PULMONARY ARTERIAL HYPERTENSION MARKET MULTI-CURRENCY
  • FIGURE 2. PULMONARY ARTERIAL HYPERTENSION MARKET MULTI-LANGUAGE
  • FIGURE 3. PULMONARY ARTERIAL HYPERTENSION MARKET RESEARCH PROCESS
  • FIGURE 4. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. PULMONARY ARTERIAL HYPERTENSION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. PULMONARY ARTERIAL HYPERTENSION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PULMONARY ARTERIAL HYPERTENSION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PULMONARY ARTERIAL HYPERTENSION MARKET DYNAMICS
  • TABLE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTANOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. PULMONARY ARTERIAL HYPERTENSION MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 192. PULMONARY ARTERIAL HYPERTENSION MARKET, FPNV POSITIONING MATRIX, 2024